share_log

VBI Vaccines Secures $100M Debt Facility From K2 HealthVentures

VBI Vaccines Secures $100M Debt Facility From K2 HealthVentures

VBI疫苗公司从K2 HealthVentures获得1亿美元的债务融资
Benzinga Real-time News ·  2022/09/15 08:32
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
VBI VBI Vaccines Inc.(纳斯达克股票代码:VBIV)(VBI)是一家由免疫学推动的生物制药公司,致力于强有力的疾病预防和治疗。该公司今天宣布,它已与现有贷款人K2 HealthVentures(K2HV)签订了一项高达1亿美元的再融资和升级债务安排,K2 HealthVentures是一家专注于医疗保健的专业金融公司。
Under the terms of the agreement, $50 million is immediately available to VBI upon closing, comprised of $30 million to refinance the outstanding facility the Company held with K2HV, and an incremental $20 million of non-dilutive funding. Future tranches of up to $25 million are committed and will be made available to VBI upon the...
根据协议条款,VBI在完成交易后可立即获得5,000万美元,其中包括3,000万美元用于对公司与K2H...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发